<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328559</url>
  </required_header>
  <id_info>
    <org_study_id>CTC</org_study_id>
    <nct_id>NCT03328559</nct_id>
  </id_info>
  <brief_title>Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer</brief_title>
  <official_title>Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pronostic value of Circulating Tumoral Cells(CTC) 's dosage by the method ISET® (tumoral
      cell isolation by size) in patients with bronchial cancer was previously demonstrated.

      However, no kinetic study was ever realized to study the value of the CTC as predictive
      indicator of answer to the therapy. This project plans to study patients in an early stage
      and patients at advance stage locally moved forward or metastatic of the disease by
      evaluation of the presence and the number of CTC before every cure. This collaborative and
      original study should allow to refine the diagnoses of answer and to plan the possible
      relapses what would allow a premature institution of the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 7, 2016</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>numeration of CTC (circulant tumoral cell)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Bronchial Cancer</condition>
  <arm_group>
    <arm_group_label>early stage bronchial cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>advanced stage bronchial cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients locally moved forward or at a metastatic stage handled by chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ISET® - Isolation by Size of Tumor cells</intervention_name>
    <description>early stage bronchial cancer patient will have a blood collection</description>
    <arm_group_label>early stage bronchial cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ISET® - Isolation by Size of Tumor cells</intervention_name>
    <description>advanced stage bronchial cancer patient will have a blood collection</description>
    <arm_group_label>advanced stage bronchial cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with non-small cell lung cancer

          -  accepting participation

        Exclusion Criteria:

          -  refusing participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean P Tredaniel, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Paris Saint Joseph</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

